Pancreatic Cancer Research

ResearcherAmsterdam UMC Location University of AmsterdamNo recent work listed

Arjan Bel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1576-6220; OpenAlex author ID A5060970719. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: 5 papers · 2018: 2 papers

Papers 12

  1. Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients. Co-author DOI 10.1016/j.ijrobp.2018.04.064↗
  2. Comparison of six fit algorithms for the intra-voxel incoherent motion model of diffusion-weighted magnetic resonance imaging data of pancreatic cancer patient… Co-author DOI 10.1371/journal.pone.0194590↗
  3. Dosimetric effects of anatomical changes during fractionated photon radiation therapy in pancreatic cancer patients. Last author DOI 10.1002/acm2.12199↗
  4. Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run. Co-author DOI 10.1007/s00066-017-1153-6↗
  5. Probabilistic treatment planning for pancreatic cancer treatment: prospective incorporation of respiratory motion shows only limited dosimetric benefit. Co-author DOI 10.1080/0284186x.2016.1257863↗
  6. Comparing the dosimetric impact of interfractional anatomical changes in photon, proton and carbon ion radiotherapy for pancreatic cancer patients. Co-author DOI 10.1088/1361-6560/aa6419↗
  7. Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: a multi-institutional study. Co-author DOI 10.1186/s13014-017-0777-0↗
  8. The impact of interfractional anatomical changes on the accumulated dose in carbon ion therapy of pancreatic cancer patients. Co-author DOI 10.1016/j.radonc.2016.03.004↗
  9. Dosimetric Advantages of Midventilation Compared With Internal Target Volume for Radiation Therapy of Pancreatic Cancer. Last author DOI 10.1016/j.ijrobp.2015.02.015↗
  10. Visibility and artifacts of gold fiducial markers used for image guided radiation therapy of pancreatic cancer on MRI. Last author DOI 10.1118/1.4918753↗
  11. EUS-guided fiducial markers placement with a 22-gauge needle for image-guided radiation therapy in pancreatic cancer. Co-author DOI 10.1016/j.gie.2013.12.027↗
  12. Limited role for biliary stent as surrogate fiducial marker in pancreatic cancer: stent and intratumoral fiducials compared. Last author DOI 10.1016/j.ijrobp.2014.03.029↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Astrid van der Horst · 10 shared papers, 2014–2017 · strength 0.63
  2. Geertjan van Tienhoven · 8 shared papers, 2014–2018 · strength 0.53
  3. E. Lens · 7 shared papers, 2014–2017 · strength 0.41
  4. Antonetta C. Houweling · 4 shared papers, 2015–2017 · strength 0.27
  5. Oliver J. Gurney‐Champion · 4 shared papers, 2015–2018 · strength 0.26
  6. Remy Klaassen · 3 shared papers, 2015–2018 · strength 0.20
  7. Aart Johannes Nederveen · 3 shared papers, 2015–2018 · strength 0.20
  8. Eva Versteijne · 3 shared papers, 2015–2017 · strength 0.20
  9. Johanna W. Wilmink · 2 shared papers, 2018 · strength 0.15
  10. Hanneke W.M. van Laarhoven · 2 shared papers, 2018 · strength 0.15
  11. Marc G. Besselink · 2 shared papers, 2018 · strength 0.15
  12. Jeanin Elise van Hooft · 3 shared papers, 2014–2015 · strength 0.14
  13. Tatsuya Ohno · 2 shared papers, 2016–2017 · strength 0.14
  14. Hanne D. Heerkens · 1 shared paper, 2017 · strength 0.07
  15. Gert J. Meijer · 1 shared paper, 2017 · strength 0.07
  16. Mustafa Suker · 1 shared paper, 2017 · strength 0.07
  17. Casper H.J. van Eijck · 1 shared paper, 2017 · strength 0.07
  18. Yoshiki Kubota · 1 shared paper, 2016 · strength 0.06
  19. G. Ebrahimi · 1 shared paper, 2017 · strength 0.06
  20. Raquel Dávila Fajardo · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.